Vytorin Derivative Suit Settlement Wins Initial Nod

Law360, New York (January 10, 2012, 6:59 PM EST) -- A New Jersey federal judge on Tuesday preliminarily approved a settlement in a shareholder derivative suit accusing former Schering-Plough Corp. directors of hiding the lackluster performance of the Merck & Co. Inc. unit's anti-cholesterol drug Vytorin for nearly two years after a clinical trial.

U.S. District Judge Dennis M. Cavanaugh signed off on the terms of the settlement, which include requirements that Merck Research Laboratories must divulge any such delays in reporting the results of clinical trials to the research committee of Merck’s board of directors,...
To view the full article, register now.